Clinical Trial Search

Primary: Progression-free Survival for at Least 6 Months (PFS-6) — 10 Percentage of participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Objective Response Rate (ORR) — 7.9 Percent of Participants

Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07

Primary: Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only — 10.0; 0; 0; 4.3 Percentage of participants

Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants

Primary: Change in Relative VO2 Peak From Baseline to Week 12 in the 4/2 and 2/1 Sunitinib Administration Schedules — -1.13; 1.27 mL/kg/min

Primary: Change From Baseline of 4- Week Average Daily Pain Measured by Visual Analog Score (VAS) Over the Period of Week 8 to 12 — -0.45; -0.37 Score on a scale — p=0.55

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12; -12; -12 score on a scale

Primary: Proportion of Patients With a Positive SARS-CoV-2 PCR — 12; 12; 11; 12 Participants

Primary: Change From Baseline in Trough FEV1 at Day 15 — 0.1904; 0.2260; -0.0222 Liters — p=<0.0001

Primary: Percentage of Participants Randomized — 100; 100 percentage of participants randomized

Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants

Primary: Number of Participants With a Complete Response — 8; 50 Participants

Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…